AlphAIAlphAI — Financial news for AI agents
globenewswire.comOCT 21 min read$MLYS

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

Mineralys Therapeutics (MLYS) will present new data from its Launch-HTN trial of lorundrostat at the American Society of Nephrology Kidney Week 2026. The trial, involving patients with uncontrolled hypertension, showed lorundrostat's potential in reducing blood pressure and albuminuria in chronic kidney disease stages 1-3. The company aims to address hypertension and related comorbidities driven by dysregulated aldosterone.

Original reporting
globenewswire.com
Published Oct 2, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$MLYS
Neutral
medium confidence
Mentioned
$MLYS
Relevance
5/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$MLYSNeutralLow
01

Why it matters

The press release signals progress but lacks efficacy data, making the immediate market move uncertain.

02

Market read

Announcement of upcoming trial data may generate speculative interest; actual impact depends on data quality.

03

What to watch

Potential regulatory delays, funding constraints, or competition from other hypertension therapies could dampen impact.

Relevance 5/10Novelty 5/10Timing: upcoming conference Oct 21-25

Background

Mineralys Therapeutics focuses on aldosterone‑related hypertension and CKD; lorundrostat is its lead candidate.

Company-level read

Ticker impact

$MLYSNeutralMedium confidence
Context

Mineralys Therapeutics announced that new Phase 3 Launch-HTN trial data for lorundrostat will be presented at the ASN Kidney Week conference.

Expected impact

potential upside if trial data exceed expectations; downside risk if data disappoint.

Evidence & confidence

Investors will price in the trial outcome after the conference; current news is an announcement without substantive results.

Market effects

Sector

May highlight the aldosterone‑synthase inhibitor space and could affect peer biotech valuations.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global relevance beyond niche hypertension/CKD therapeutic segment.

Counterpoint

What could challenge this read

Without disclosed efficacy data, the announcement may be overhyped; investors could wait for actual results before acting.

Key entities

  • company
    Mineralys Therapeutics

    Biopharma developing lorundrostat for hypertension and CKD.

  • event
    American Society of Nephrology (ASN) Kidney Week

    Conference where the trial data will be presented.

Read at source← All news

Related articles

OCT 12
$MLYSHigh

H.C. Wainwright reiterates Mineralys stock rating on new data

H.C. Wainwright reiterated a Buy rating and $56.00 price target for Mineralys Therapeutics (NASDAQ:MLYS), citing new clinical data for lorundrostat. The target implies 140% upside from the current stock price of $23.37. The firm highlights the drug's potential in treating difficult-to-treat hypertension ahead of a December 2026 PDUFA date. Mineralys reported a wider-than-expected Q2 2026 loss of $2.85 per share. UBS initiated coverage with a Neutral rating and $29.00 price target.

investing.com2 min
OCT 9
$MLYSHighAI 9/10

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Mineralys Therapeutics (MLYS) presented data at the American Heart Association Hypertension Scientific Sessions 2026. In the Launch-HTN trial, 46% of participants with difficult-to-treat hypertension achieved the AHA/ACC systolic blood pressure target of <130 mmHg with lorundrostat 50 mg. In the Explore-OSA trial, lorundrostat reduced morning systolic blood pressure by 11.1 mmHg at Week 4. Both trials showed favorable safety and tolerability profiles for lorundrostat.

globenewswire.com2 min
AUG 22
$MLYSMed

Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention

Mineralys Therapeutics (MLYS) reported a Q2 2026 net loss of $241.07M. The company appointed James J. Ferguson III, M.D., as Chief Medical Officer. Shares are down 5.04% in 30 days and 14.07% in 90 days, but up 72.32% in 1 year and 97.31% in 3 years. Analysts suggest fair value at $50.88, above the current $25.65, based on lorundrostat's potential. Risks include regulatory outcomes and cash burn.

simplywall.st2 min
AUG 19
$MLYSMed

Mineralys (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics (MLYS) reported Q2 2026 earnings, highlighting a net loss of $241.1 million due to royalty repurchase obligations. Key financial activities included a $150 million equity offering and a $100 million tranche from a $500 million loan. The company is preparing for the FDA's PDUFA date for lorundrostat, a hypertension treatment, with commercial launch plans and payer discussions underway. Management expressed optimism about the regulatory review and market potential.

fool.com4 min
AUG 13
$MLYSMed

Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary

Mineralys Therapeutics reported Q2 2026 updates on lorundrostat. The company said it repurchased future royalties from Mitsubishi Tanabe for $200 million, secured a $500 million senior secured term loan, and completed a $150 million equity offering. R&D rose to $221.4 million. It cited LAUNCH-HTN results and targeted a Dec. 22, 2026 PDUFA, with FDA discussions in Oct-Nov 2026.

yahoo.com7 min